WallStSmart
CRDL

Cardiol Therapeutics Inc Class A

NASDAQ: CRDL · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$1.35
-3.48% today

Updated 2026-06-05

Market cap
$130.26M
P/E ratio
P/S ratio
1,014.87x
EPS (TTM)
$-0.28
Dividend yield
52W range
$1 – $2
Volume
0.7M

Cardiol Therapeutics Inc Class A (CRDL) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item201720182019202020212022202320242025
Operating cash flow$-1.29M$-10.89M$-11.38M$-9.13M$-23.55M$-27.22M$-25.18M$-25.06M$-23.85M
Capital expenditures$29171.00$13791.00$424305.00$40602.00$12916.00$74709.00$64312.00$21290.00$24484.00
Depreciation
Stock-based comp$237.00$1.65M$3.27M$2.77M$8.50M$5.01M$4.16M$14.28M$10.70M
Free cash flow$-1.32M$-10.91M$-11.80M$-9.17M$-23.56M$-27.30M$-25.24M$-25.08M$-23.88M
Investing cash flow
Financing cash flow
Dividends paid
Share repurchases
Debt repayment
Net change in cash

Frequently asked questions

How much free cash flow does CRDL generate?

CRDL produced $-23.88M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is CRDL's balance sheet healthy?

CRDL holds $21.42M in cash and equivalents against — in long-term debt, on $17.88M of shareholder equity. That debt is best read against the cash flow the business throws off each year.